Osteoporosis - primary prevention
Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Summary
Whether or not a postmenopausal woman with osteoporosis is offered one of these drugs to prevent bone fractures will depend on her age, her bone density and how many risk factors for fracture and indicators of fragile bones she has. In principle, alendronate is recommended as a possible treatment f ...
Update 29 January 2010
NICE has today announced that, following consultation with stakeholders on the economic model that underpinned NICE's 2008 guidance on the use of drugs for the prevention and treatment of osteoporotic fragility fractures in postmenopausal women, the resulting guidance remains unchanged.
In accordance with the Court’s ruling on the technology appraisals of drugs for the prevention and treatment of osteoporotic fragility fractures in postmenopausal women, NICE released the fully executable economic model to stakeholders for their comment in May 2009. Having reviewed all the resulting comments, the independent Appraisal Committee concluded that the economic model was an appropriate basis for the previously made recommendations, and that the recommendations should therefore remain unchanged. Consultees then had a chance to appeal against this decision but no appeals were received.
NICE guidance on the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the prevention and treatment of osteoporotic fragility fractures in postmenopausal women therefore remains unchanged.
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in July 2010
About this guidance
Technology appraisals TA160
Issued: October 2008
How this guidance was produced